目的:这项比较前瞻性研究是在皮肤科进行的,巴基斯坦阿联酋军队医院,拉瓦尔品第,从2018年8月1日至2019年1月31日(六个月)。本研究旨在比较病灶内氯喹与病灶内抗蒙酸葡甲胺治疗皮肤利什曼病的疗效。
方法:共有64例符合纳入标准的患者向皮肤科报告,本研究纳入了白阿联酋军队医院。知情同意和人口统计数据,包括患者医院登记号,年龄,性别,并记录病变数量。将受试者随机分为两组。在A组中,每周注射两次病灶内氯喹,在B组中,每周注射2次.治疗八周后注意到两种治疗的功效。计算定性变量如性别和病变数量的频率和百分比。对于年龄等定量变量,给出了平均值±标准偏差。分析比较两组的比例。采用卡方检验比较两组疗效,p≤0.05为显著。
结果:在这项研究中,患者的平均年龄为29.69±08.95岁。男性63人(98.44%),女性1人(1.56%)。在这项研究中,A组6例(18.8%)患者达到疗效,而B组17例(53.1%)患者,差异有统计学意义,即,p=0.004。
结论:本研究的结论是,与病灶内的氯喹相比,病灶内的抗蒙酸葡甲胺更有效地治疗皮肤利什曼病。
OBJECTIVE: This comparative prospective study was conducted at the Department of Dermatology, Pak Emirates Military Hospital, Rawalpindi, from August 1, 2018, to January 31, 2019 (six months). This study aimed to compare the efficacy of
intralesional chloroquine with
intralesional meglumine antimoniate in the treatment of cutaneous leishmaniasis.
METHODS: A total of 64 patients fulfilling the inclusion criteria reporting to the Department of Dermatology, Pak Emirates Military Hospital were included in this study. Informed consent was taken and demographic data including patients\' hospital registration number, age, gender, and number of lesions were noted. The subjects were randomly assigned into two groups. In group A,
intralesional chloroquine was injected two times per week, and in group B,
intralesional meglumine antimoniate was injected two times per week. The efficacy of both treatments was noted after eight weeks of treatment. Frequency and percentages were computed for qualitative variables like gender and number of lesions. Mean±standard deviation was presented for quantitative variables like age. Analysis was done to compare the proportion of both groups. Chi-square test was applied to compare the efficacy of both groups, p≤0.05 was taken as significant.
RESULTS: In this study, the mean age of patients was 29.69±08.95 years. There were 63 (98.44%) males and one (1.56%) female. In this study, efficacy was achieved in six (18.8%) patients in group A, while in 17 (53.1%) patients in group B. This difference was statistically significant, i.e., p=0.004.
CONCLUSIONS: This study concluded that
intralesional meglumine antimoniate is more effective in treating cutaneous leishmaniasis than
intralesional chloroquine.